MedTrace Logo

Economic Evaluation of the Use of Plerixafor for Autologous HSC Transplantation for Multiple Myeloma

NCT02861287 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2016-08-10

No results posted yet for this study

Summary

This study aims to realize an economic evaluation of the introduction of Plerixafor in addition to G-CSF and alternative options, in patients with multiple myeloma (MM) who failed or insufficiently mobilize peripheral blood stem and progenitor cells in response to G-CSF alone.

Conditions

Interventions

OTHER

Economic evaluation

Sponsors & Collaborators

  • Institut Paoli-Calmettes

    lead OTHER

Principal Investigators

  • Christian Chabannon, MD PhD · Institut Paoli-Calmettes

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2015-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02861287 on ClinicalTrials.gov